Details
Stereochemistry | RACEMIC |
Molecular Formula | C20H21NO4 |
Molecular Weight | 339.385 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(OC)C2=C(CC3N(CCC4=CC5=C(OCO5)C=C34)C2)C=C1
InChI
InChIKey=VZTUIEROBZXUFA-UHFFFAOYSA-N
InChI=1S/C20H21NO4/c1-22-17-4-3-12-7-16-14-9-19-18(24-11-25-19)8-13(14)5-6-21(16)10-15(12)20(17)23-2/h3-4,8-9,16H,5-7,10-11H2,1-2H3
Canadine (tetrahydroberberine,THB) is an isoquinoline alkaloid (5,8,13,13a-tetrahydro-9,10-dimethoxy-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizine) from Corydalis tuber, it has micromolar affinity for dopamine D(2) (pK(i) = 6.08) and 5-HT(1A) (pK(i) = 5.38) receptors but moderate to no affinity for other relevant serotonin receptors (i.e., 5-HT(1B), 5-HT(1D), 5-HT(3), and 5-HT(4). Canadine enhances gastrointestinal motor function. THB, with D(2) receptor antagonist and 5-HT(1A) receptor agonist properties, has significant potential as a therapeutic for treatment of functional dyspepsia. THB is a potent inhibitor of platelet aggregation in vitro and in vivo and is a promising antithrombotic drug.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL217 |
119.0 nM [Ki] | ||
Target ID: CHEMBL214 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21659472 |
5.38 null [pKi] | ||
Target ID: GO:0070527 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8010106 |
0.86 mM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Preventing | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
In vitro anti-proliferation/cytotoxic activity of sixty natural products on the human SH-SY5Y neuroblastoma cells with specific reference to dibenzyl trisulphide. | 2004 Sep |
|
Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing. | 2014 Jan |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21659472
Rats: Oral administration of Canadine not only resulted in the significantly accelerated gastric emptying of normal rats in a bell-shaped relationship, with a maximal efficacy at a dose of 30 ug/kg, but also restored the delayed gastric emptying caused by apomorphine, which might be mediated by an antidopaminergic effect.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12515216
Canadine (tetrahydroberberine,THB) (0.1-10 uM/L) shifted the dose-response curves to the right in a nonparallel fashion and decreased the maximal response (Emax) of both the fenoldopam(FODA, a selective DA1 agonist)-induced and the propyl-butyl-dopamine(PBDA, a selective DA2 agonist)-induced vasorelaxation, showing a non-competitive antagonistic action. The pD'2 values of THB for FODA in the renal, pulmonary and mesenteric arteries were 5.29, 5.37 and 5.46, respectively, while for PBDA in the mesenteric and femoral arteries were 5.53 and 5.48, respectively.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CANADINE
Created by
admin on Sat Dec 16 02:10:55 GMT 2023 , Edited by admin on Sat Dec 16 02:10:55 GMT 2023
|
PRIMARY | |||
|
22998
Created by
admin on Sat Dec 16 02:10:55 GMT 2023 , Edited by admin on Sat Dec 16 02:10:55 GMT 2023
|
PRIMARY | |||
|
28111-09-3
Created by
admin on Sat Dec 16 02:10:55 GMT 2023 , Edited by admin on Sat Dec 16 02:10:55 GMT 2023
|
SUPERSEDED | |||
|
36351
Created by
admin on Sat Dec 16 02:10:55 GMT 2023 , Edited by admin on Sat Dec 16 02:10:55 GMT 2023
|
PRIMARY | |||
|
DTXSID5022724
Created by
admin on Sat Dec 16 02:10:55 GMT 2023 , Edited by admin on Sat Dec 16 02:10:55 GMT 2023
|
PRIMARY | |||
|
C004645
Created by
admin on Sat Dec 16 02:10:55 GMT 2023 , Edited by admin on Sat Dec 16 02:10:55 GMT 2023
|
PRIMARY | |||
|
m3008
Created by
admin on Sat Dec 16 02:10:55 GMT 2023 , Edited by admin on Sat Dec 16 02:10:55 GMT 2023
|
PRIMARY | Merck Index | ||
|
26548-75-4
Created by
admin on Sat Dec 16 02:10:55 GMT 2023 , Edited by admin on Sat Dec 16 02:10:55 GMT 2023
|
SUPERSEDED | |||
|
34458
Created by
admin on Sat Dec 16 02:10:55 GMT 2023 , Edited by admin on Sat Dec 16 02:10:55 GMT 2023
|
PRIMARY | |||
|
94918
Created by
admin on Sat Dec 16 02:10:55 GMT 2023 , Edited by admin on Sat Dec 16 02:10:55 GMT 2023
|
PRIMARY | |||
|
29074-38-2
Created by
admin on Sat Dec 16 02:10:55 GMT 2023 , Edited by admin on Sat Dec 16 02:10:55 GMT 2023
|
SUPERSEDED | |||
|
V2SSH085X8
Created by
admin on Sat Dec 16 02:10:55 GMT 2023 , Edited by admin on Sat Dec 16 02:10:55 GMT 2023
|
PRIMARY | |||
|
522-97-4
Created by
admin on Sat Dec 16 02:10:55 GMT 2023 , Edited by admin on Sat Dec 16 02:10:55 GMT 2023
|
PRIMARY | |||
|
208-338-2
Created by
admin on Sat Dec 16 02:10:55 GMT 2023 , Edited by admin on Sat Dec 16 02:10:55 GMT 2023
|
PRIMARY | |||
|
4979-14-0
Created by
admin on Sat Dec 16 02:10:55 GMT 2023 , Edited by admin on Sat Dec 16 02:10:55 GMT 2023
|
SUPERSEDED |
SUBSTANCE RECORD